about
Single-molecule study of the CUG repeat-MBNL1 interaction and its inhibition by small molecules.Functional KCa1.1 channels are crucial for regulating the proliferation, migration and differentiation of human primary skeletal myoblastsDiagnostic odyssey of patients with myotonic dystrophyAntisense therapy in neurologySmaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.Tibialis anterior muscle needle biopsy and sensitive biomolecular methods: a useful tool in myotonic dystrophy type 1Myotonic dystrophy type 1 associated with white matter hyperintense lesions: clinic, imaging, and genetic analysisChronic muscle stimulation improves muscle function and reverts the abnormal surface EMG pattern in myotonic dystrophy: a pilot studyA Potent Inhibitor of Protein Sequestration by Expanded Triplet (CUG) Repeats that Shows Phenotypic Improvements in a Drosophila Model of Myotonic Dystrophy.Pre-mRNA splicing in disease and therapeutics.How do C9ORF72 repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders?Gene-based therapies of neuromuscular disorders: an update and the pivotal role of patient organizations in their discovery and implementation.Development of pharmacophore models for small molecules targeting RNA: Application to the RNA repeat expansion in myotonic dystrophy type 1.Major involvement of trunk muscles in myotonic dystrophy type 1.Review of patient-reported outcome measures for use in myotonic dystrophy type 1 patients.Myotonic Dystrophy Health Index: initial evaluation of a disease-specific outcome measure.A novel CUG(exp)·MBNL1 inhibitor with therapeutic potential for myotonic dystrophy type 1.Cost of illness for neuromuscular diseases in the United States.miR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models.
P2860
Q30541488-D4FE4E01-35CC-4B6D-A6F4-0C99B88A5ED7Q30830556-8C01F3CA-78C9-429B-BABB-458F82FD7FB1Q34172180-5E5CB74D-19FE-4191-ACED-7F6AE62C4BC2Q34608717-E587E827-DFB9-4289-84FD-7EE0D2C96C5FQ34699771-050855F7-2A4C-4309-A52E-063DAF75E091Q35031314-636C4258-64AB-4334-8C46-5FAE3C9D29C6Q36423096-CE24C7C2-D937-425D-9AA0-104F9E37CFBAQ36794513-18058A3B-8CCA-407D-AED5-50FD13DA8E54Q37152085-D2F7D43D-6041-4212-B99A-C271614FFF65Q37358384-341E48A1-1BDB-4E1D-9A61-DE5C358AF599Q38028093-2917572C-456F-408D-9371-6CAE585BD723Q38060527-906F3856-FFA4-4E9A-BDDD-99D7C63875FBQ38152406-18A917DC-5259-4B34-9866-CB1D79F35D57Q38434922-C13382BD-0D50-41F3-BA29-5B7C6569F7E2Q38809790-C8CACE69-17DE-44CE-9A58-74DF3BA3F8DFQ39012912-E2B1DD99-FA7E-4D7D-80F8-160C70D63CA5Q41345571-1AEEB52C-D477-4C68-B32C-62224B9816EDQ41825220-9A0CE0A7-36E3-447D-848B-5BF11ED281E8Q43841798-CEA35335-9787-4A10-A08E-26FD5A3F4BDAQ55418837-D3B65C84-A0C3-419E-BC20-E39B641C8CE1
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Therapeutics development in myotonic dystrophy type 1.
@ast
Therapeutics development in myotonic dystrophy type 1.
@en
type
label
Therapeutics development in myotonic dystrophy type 1.
@ast
Therapeutics development in myotonic dystrophy type 1.
@en
prefLabel
Therapeutics development in myotonic dystrophy type 1.
@ast
Therapeutics development in myotonic dystrophy type 1.
@en
P2860
P356
P1433
P1476
Therapeutics development in myotonic dystrophy type 1.
@en
P2093
Erin Pennock Foff
Mani S Mahadevan
P2860
P304
P356
10.1002/MUS.22090
P577
2011-05-23T00:00:00Z